PCSK9 Inhibitors Market

DelveInsight’s PCSK9 Inhibitors market report provides an in-depth understanding of the PCSK9 Inhibitors, historical and forecasted epidemiology, as well as PCSK9 Inhibitors market trends in the 7MM. The PCSK9 Inhibitors market report also covers current treatment practices, emerging drugs, PCSK9 Inhibitors market share of individual therapies.

Some of the Key Highlights from the PCSK9 Inhibitors Market Report

• According to the National Organization for Rare Disorders (NORD), Familial Hypercholesterolemia is one of the most common genetic diseases, affecting approximately one in every 250 people.

• As per DelveInsight estimates, the Familial Hypercholesterolemia diagnosed cases were 322,852 in the US in 2020, which is further expected to increase by 2030.

• As per the estimates, the total Familial Hypercholesterolemia prevalent cases were 1,270,635 in EU5 in 2020. 

• The leading players active in the PCSK9 Inhibitors market include LIB Therapeutics, Ionis Pharmaceuticals, AstraZeneca, CiVi Biopharma, and others.

• Key PCSK9 Inhibitors therapies in the pipeline include LIB003 (Lerodalcibep), AZD8233 (ION449), CIVI 007,  and others.

• AZD8233 (ION449), formerly IONIS-AZ4-2.5-LRx, is an investigational ligand-conjugated antisense medicine. As part of a collaboration between Ionis Pharmaceuticals and AstraZeneca, AstraZeneca is developing ION449.

• CiVi 007 is a long-acting, third-generation PCSK9 in development by CiVi Biopharma to treat hypercholesterolemia and prevent atherosclerotic cardiovascular disease (ASCVD).

• The PCSK9 Inhibitors market size is anticipated to increase with a CAGR of 16.5% by 2030. 

Have queries? Request for the sample @ PCSK9 Inhibitors Market Outlook

PCSK9 Inhibitors Overview

Proprotein convertase subtilisin/Kexin type 9 (PCSK9) regulates the degradation of low-density lipoprotein (LDL) receptors, which is important in cholesterol metabolism. It promotes the degradation of low-density lipoprotein (LDL) receptors, reducing the clearance of circulating LDL particles.

PCSK9 Inhibitors Epidemiology Segmentation

The PCSK9 Inhibitors report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Familial Hypercholesterolemia Total Prevalent Cases

• Familial Hypercholesterolemia Total Diagnosed Cases

• Familial Hypercholesterolemia Type-Specific Cases

• Familial Hypercholesterolemia Age Group-Specific Cases

• Familial Hypercholesterolemia Mutation-Specific Cases

• PCSK9 Inhibitors Risk Factors-Specific Cases in Prophylactic/Preventive Setting

• PCSK9 Inhibitors Total Treated Cases

PCSK9 Inhibitors Treatment Landscape

There are currently two PCSK9 inhibitors available in the United States: Alirocumab and Evolocumab, which the FDA has approved for adult patients to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalisation in adults with established cardiovascular disease as an adjunct to diet, alone or in combination with other lipid-lowering therapies, for the treatment of adults with primary hyperlipidemia (including HeFH) to reduce LDL-cholesterol.

PCSK9 Inhibitors Market Outlook

The PCSK9 Inhibitors market size is anticipated to increase with a CAGR of 16.5% by 2030. The PCSK9i market is expected to grow significantly due to the use of PCSK9 inhibitors in statin-intolerant patients, promising future PCSK9 inhibition strategies, implications of PCSK9 inhibitors in broader therapy areas, and PCSK9 inhibition in a prophylactic setting, which can reduce CVD burden.

PCSK9 Inhibitors Pipeline Therapies and Key Companies 

• LIB003 (Lerodalcibep): LIB Therapeutics

• AZD8233 (ION449): Ionis Pharmaceuticals/AstraZeneca

• CIVI 007: CiVi Biopharma

For complete information on the emerging therapies, visit @ PCSK9 Inhibitors Drugs

PCSK9 Inhibitors Market Drivers

• Use of PCSK9 inhibitors in statin-intolerant patients

• PCSK9 inhibition in a prophylactic setting can relieve the CVD burden

• Promising future strategies of PCSK9 inhibition

• Implications of PCSK9 inhibitors in broader therapy areas

PCSK9 Inhibitors Market Barriers

• Premium pricing of the drugs has resulted in low commercial uptake

• Lack of long-term safety and efficacy data

• Commercial payer actions affect market access and sales of Repatha

• Strict reimbursement scenario in the 7MM

• Use of off-label therapies and generics

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

PCSK9 Inhibitors Key Companies: LIB Therapeutics, Ionis Pharmaceuticals, AstraZeneca, CiVi Biopharma, among others. 

PCSK9 Inhibitors Key Pipeline Therapies: LIB003 (Lerodalcibep), AZD8233 (ION449), CIVI 007, and others.

PCSK9 Inhibitors Segmentation: By Geography, By PCSK9 Inhibitors therapies

Analysis: Comparative and conjoint analysis of PCSK9 Inhibitors emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

Get in touch with our business executive for Healthcare Due Diligence Services

Related Reports

Familial Hypercholesterolemia Market

Get a comprehensive analysis of Familial Hypercholesterolemia pipeline therapies and key companies such as Sanofi, Regeneron Pharmaceuticals, Amgen, Esperion Therapeutics, Regeneron Pharmaceuticals, Novartis, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/